Migraine drug could soothe stubborn facial pain

NCT ID NCT07250984

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This small study tests whether eptinezumab, a drug used for migraines, can reduce pain in people with atypical facial pain that hasn't responded to other treatments. Ten participants will receive two intravenous infusions three months apart. The main goal is to see if the drug improves daily functioning, measured by a migraine disability questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

eptinezumab (ACMP)

What this could lead to

If it works, this could point toward a new treatment option for people with persistent facial pain that is hard to treat.

What could go wrong

This is a very small, early-stage trial with only 10 participants. It may not show clear benefit, and results may not apply to everyone with facial pain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FACIAL PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

facial neuralgia Facial Pain persistent idiopathic facial pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pain Therapy Clinic of University Medical Centre Ljubljana

    Ljubljana, 1000, Slovenia